Appropriate PD-L1 Cutoff Value for Gastric Cancer Immunotherapy: A Systematic Review and Meta-Analysis

被引:31
|
作者
Xie, Tong [1 ]
Zhang, Zhening [1 ]
Zhang, Xiaotian [1 ]
Qi, Changsong [1 ]
Shen, Lin [1 ]
Peng, Zhi [1 ]
机构
[1] Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ, Beijing, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
基金
中国国家自然科学基金;
关键词
immunotherapy; chemotherapy; PD-L1; cutoff value; gastric cancer; EFFICACY; SAFETY; COMBINATION; NIVOLUMAB; CHEMO;
D O I
10.3389/fonc.2021.646355
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Immunotherapy dramatically changed the treatment landscape of gastric cancer in recent years. PD-L1 expression was proposed as a biomarker; however, the treatment strategy according to PD-L1 is still uncertain. Here, we aimed to find the appropriate cutoff value of PD-L1 expression for gastric cancer immunotherapy.</p> Methods We did a systematic electronic research of prospective clinical trials of gastric cancer immunotherapy across databases. Studies that provided subgroup analysis results stratified by PD-L1 expression were included. Objective response rate (ORR), disease control rate (DCR), hazard ratio (HR), and 95% confidential interval (CI) of progression-free survival (PFS) and overall survival (OS) at different PD-L1 cutoff values were extracted.</p> Results Twelve studies and 6,488 patients in total were finally included for pooled analysis. ORR in allover, PD-L1-negative, combined positive score (CPS) >= 1, CPS >= 5, and CPS >= 10 population was 10%, 3%, 13%, 20%, and 23%, respectively. Immune checkpoint inhibitor (ICI) monotherapy failed to show survival advantage in allover and PD-L1-negative patients. Single-agent ICI therapy prolonged OS (HR = 0.84, 95% CI: 0.74-0.96) but not PFS (HR = 1.38, 95% CI: 0.91-2.09) in PD-L1 CPS >= 1 patients. For combined immunotherapy, ORR in allover, PD-L1-negative, CPS >= 1, CPS >= 5, and CPS >= 10 population was 64%, 57%, 48%, 60%, and 58%, respectively. Allover population could gain survival benefit from combined immunotherapy based on the results from Checkmate-649. OS (HR = 0.81, 95% CI: 0.71-0.92) and PFS (HR = 0.77, 95% CI: 0.69-0.86) were significantly prolonged in PD-L1 CPS >= 1 patients receiving combined immunotherapy.</p> Conclusion Efficacy and survival advantages improved with PD-L1 CPS. CPS >= 1 was the cutoff value for ICI monotherapy to gain survival benefit. Combined immunotherapy prolonged PFS and OS in allover population but needs further study to confirm it.</p>
引用
收藏
页数:10
相关论文
共 50 条
  • [1] PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis
    Gu, Lihu
    Chen, Manman
    Guo, Dongyu
    Zhu, Hepan
    Zhang, Wenchao
    Pan, Junhai
    Zhong, Xin
    Li, Xinlong
    Qian, Haoran
    Wang, Xianfa
    [J]. PLOS ONE, 2017, 12 (08):
  • [2] The Anti-PD-1/PD-L1 Immunotherapy for Gastric Esophageal Cancer: A Systematic Review and Meta-Analysis and Literature Review
    Chen, Ke
    Wang, Xiao
    Yang, Liu
    Chen, Zheling
    [J]. CANCER CONTROL, 2021, 28
  • [3] PD-L1 expression in EBV associated gastric cancer: a systematic review and meta-analysis
    Áurea Lima
    Hugo Sousa
    Rui Medeiros
    Amanda Nobre
    Manuela Machado
    [J]. Discover Oncology, 13
  • [4] PD-L1 expression in EBV associated gastric cancer: a systematic review and meta-analysis
    Lima, Aurea
    Sousa, Hugo
    Medeiros, Rui
    Nobre, Amanda
    Machado, Manuela
    [J]. DISCOVER ONCOLOGY, 2022, 13 (01)
  • [5] Prognostic and clinicopathological value of PD-L1 in colorectal cancer: a systematic review and meta-analysis
    Yang, Lianzhou
    Xue, Rujun
    Pan, Chunhua
    [J]. ONCOTARGETS AND THERAPY, 2019, 12 : 3671 - 3682
  • [6] PD-L1 expression in vulvar cancer: a systematic review and meta-analysis
    Baandrup, Louise
    Sand, Freja Laerke
    Aalborg, Gitte Lerche
    Nottrup, Trine J.
    Fiehn, Anne-Marie K.
    Kjaer, Susanne K.
    [J]. HISTOPATHOLOGY, 2024, 84 (05) : 742 - 752
  • [7] Evaluation of PD-L1 as a biomarker for immunotherapy for hepatocellular carcinoma: systematic review and meta-analysis
    Zhou, Xueyin
    Cao, Jiasheng
    Topatana, Win
    Xie, Tianao
    Chen, Tianen
    Hu, Jiahao
    Li, Shijie
    Juengpanic, Sarun
    Lu, Ziyi
    Zhang, Bin
    Wang, Kaitai
    Feng, Xu
    Shen, Jiliang
    Chen, Mingyu
    [J]. IMMUNOTHERAPY, 2023, 15 (05) : 353 - 365
  • [8] Predictive value of PD-L1 expression in response to immune checkpoint inhibitors for gastric cancer treatment: a systematic review and meta-analysis
    Noori, Maryam
    Fayyaz, Farimah
    Zali, Mohammad Reza
    Bashash, Davood
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (09) : 1029 - 1039
  • [9] PD-L1 is associated with the prognosis of penile cancer: A systematic review and meta-analysis
    Lu, Yi
    Wang, Yutao
    Su, Hao
    Li, Hongjun
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [10] The predictive value of PD-L1 expression in response to anti-PD-1/PD-L1 therapy for biliary tract cancer: a systematic review and meta-analysis
    Yoon, Seung Bae
    Woo, Sang Myung
    Chun, Jung Won
    Kim, Dong Uk
    Kim, Jaihwan
    Park, Joo Kyung
    So, Hoonsub
    Chung, Moon Jae
    Cho, In Rae
    Heo, Jun
    [J]. FRONTIERS IN IMMUNOLOGY, 2024, 15